ImmunityBio Inc (NASDAQ:IBRX) shares, rose in value on Wednesday, April 16, with the stock price down by -10.79% to the previous day’s close as strong demand from buyers drove the stock to $2.48.
Actively observing the price movement in the last trading, the stock closed the session at $2.78, falling within a range of $2.39 and $2.75. The value of beta (5-year monthly) was -0.127. Referring to stock’s 52-week performance, its high was $10.53, and the low was $2.28. On the whole, IBRX has fluctuated by -11.74% over the past month.
With the market capitalization of ImmunityBio Inc currently standing at about $2.19 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-02.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 104.03M, with a low estimate of 13.78M and a high estimate of 16.7M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 15.66M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that IBRX’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of IBRX currently trading nearly -11.63% and -17.45% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 41.86, while the 7-day volatility ratio is showing 11.73% which for the 30-day chart, stands at 10.25%. Furthermore, ImmunityBio Inc (IBRX)’s beta value is 0.21, and its average true range (ATR) is 0.30.
A comparison of ImmunityBio Inc (IBRX) with its peers suggests the former has fared considerably weaker in the market. IBRX showed an intraday change of -10.79% in last session, and over the past year, it shrunk by -52.67%%.
Data on historical trading for ImmunityBio Inc (NASDAQ:IBRX) indicates that the trading volumes over the past 10 days have averaged 9.04 and over the past 3 months, they’ve averaged 6.76 million. According to company’s latest data on outstanding shares, there are 852.74 million shares outstanding.
Nearly 89.60% of ImmunityBio Inc’s shares belong to company insiders and institutional investors own 9.59% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 63.18 million shares as on 2025-03-31, resulting in a short ratio of 10.24. According to the data, the short interest in ImmunityBio Inc (IBRX) stood at 1985.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 60.93 million. The stock has fallen by -3.12% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the IBRX stock heading into the next quarter.
